Phase 3 N=323 Mycotic Ulcer Treatment Trial I
Corneal Ulcer · Eye Infections, Fungal
Primary: Best Spectacle-corrected logMAR Visual Acuity — 0.39; 0.57 logMAR — p=0.006
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=70 Mycotic Antimicrobial Localized Injection for Treatment of Corneal Ulcers
Corneal Ulcer · Fungal Keratitis
Primary: Culture Positivity at Day 3 Using Potassium Hydroxide (KOH) Wet Mount to Test for Fungus — 14; 11 Participants — p=0.26
Phase 3 N=240 The Mycotic Ulcer Treatment Trial II: A Randomized Trial Comparing Oral Voriconazole vs Placebo
Corneal Ulcer · Eye Infections, Fungal
Primary: Incidence of Perforation or Therapeutic Penetrating Keratoplasty — 0.0095562; 0.011204 New perforations or TPK/person-days — p=0.29
Phase 2 N=120 Therapeutic Exploratory Study of Comparing Natamycin and Voriconazole to Treat Fungal Corneal Ulcer
Fungal Keratitis
Primary: Best Spectacle Corrected Visual Acuity (BSCVA) 3 Months After Enrollment, Adjusting for Enrollment BSCVA in a Multiple Linear Regression Model — 0.61; 0.71 logMAR — p=0.29
Phase 3 N=147 Cross-linking for Corneal Ulcers Treatment Trial
Corneal Ulcer · Infectious Keratitis · Bacterial Ulcer
Primary: Microbiological Cure on Repeat Culture — 5; 5; 17; 14 Participants
N/A N=15 Mucinex® for Treatment of Filamentary Keratitis
Filamentary Keratitis
Primary: Change in Number of Corneal Filaments — 5.8; 2.1 corneal filaments — p=<0.04
Phase 3 N=330 Rose Bengal Electromagnetic Activation With Green Light for Infection Reduction
Acanthamoeba Keratitis · Fungal Keratitis
Primary: Best Spectacle-Corrected Visual Acuity — 0.614; 0.666 logMAR
Phase 3 N=134 Polihexanide (PHMB) Eye Drops in Patients Affected by Acanthamoeba Keratitis
Acanthamoeba Keratitis
Primary: Clinical Resolution Rate — 84.8; 88.5 percentage of participants
N/A N=239 Anti-mold Azole in the Prophylaxis for Invasive Fusariosis
Fusariosis · Onychomycosis
Primary: Proportion of Patients Who Develop Invasive Fusariosis Until Neutrophil Recovery — 6; 8 Participants
N/A N=18 Corneal Topographer Fluorescein Patterns
Keratoconus
Primary: Number of Participants With an Observable Difference Between Virtual Versus Actual Fluorescein Patterns — 0 participants
Phase 2 N=510 Corneal Crosslinking in Patients With Keratoconus and Post-Refractive Ectasia
Keratoconus · Post-Refractive Ectasia
Primary: Change in Maximum Keratometry From Baseline to 6 Months After Treatment — 0.76; 0.97 diopters
Phase 2 N=1 Use of Cross-linked Donor Corneas as Carriers for the Boston Keratoprosthesis
Chemical Injuries · Unspecified Complication of Corneal Transplant · Autoimmune Diseases
Primary: Changes in Corneal Thickness at 1 Millimeter — 730; 760; 700; 720 micrometer
Phase 4 N=500 Steroids for Corneal Ulcers Trial
Corneal Ulcer · Eye Infections, Bacterial
Primary: Best Spectacle-corrected Visual Acuity (BSCVA) in logMAR at 3 Months, Using Best Spectacle-corrected Enrollment Visual Acuity as a Co-variate — 0.48; 0.49 logMAR — p=0.82
Phase 4 N=36 Impact of Acthar on Everyday Life of Participants With Severe Keratitis
Keratitis
Primary: Number of Participants Who Improved on the Impact of Dry Eye on Everyday Life (IDEEL) Scale [Using the Symptom Bother Module at Week 12] — 17 Participants
Phase 2 N=131 Study to Evaluate the Safety and Efficacy of CSB-001 Ophthalmic Solution 0.1% in Neurotrophic Keratitis Subjects
Neurotrophic Keratitis
Primary: Efficacy as Assessed by Complete Corneal Healing — 21; 16 Participants
Phase 4 N=13 Antifungal Locks to Treat Fungal-related Central Line Infections
Central Line Fungal Infections
Primary: Number of Patients With 2 Negative Fungal Cultures After 5 Days of Combined Systemic Antifungal and Antifungal Lock Therapy and the CVC Was Not Removed — 10; 3…
Phase 3 N=147 Corneal Collagen Cross-linking for Progressive Keratoconus
Progressive Keratoconus
Primary: Mean Change From Baseline in Maximum Keratometry (Kmax) — -1.7; 0.6 diopters
Phase 2 N=68 Vision Restoration With a Collagen Crosslinked Boston Keratoprosthesis Unit
Keratolysis
Primary: Time From Surgery to Device Loss or Replacement — 95; 34 median weeks from surgery to removal
N/A N=399 Surveillance of Ocular Surface Flora (SURFACE)
Cataract
Primary: Percentage of Staphylococcus Epidermidis Species Susceptible and Resistant to Oxacillin on the Eyelid — 51; 48 Percentage of Species
Phase 2 N=10 A Study of the KIO-201 (Ocular Bandage Gel) for Improving Persistent Corneal Epithelial Defects
Persistent Corneal Epithelial Defect
Primary: Percentage of Patients Achieving Corneal Healing (<0.5 mm2 Lesion Size) of the Persistent Corneal Epithelial Defect at 4 Weeks — 5 Participants
Phase 2 N=108 REC 0/0559 Eye Drops for Treatment of Moderate and Severe Neurotrophic Keratitis in Adult Patients
Neurotrophic Keratitis
Primary: Corneal Healing — 4; 2; 1; 2 Participants
Phase 2 N=65 Study to Investigate the Safety and Efficacy of K-321 in Patients With Fuchs Endothelial Corneal Dystrophy (FECD) Following Descemetorhexis
Fuchs' Endothelial Corneal Dystrophy
Primary: Central Corneal Endothelial Cell Density (ECD) at Week 12 — 530.86; 468.02; 228.05 cells/mm2 — p=0.0065
N/A N=23 A Study Of Indian Patients Receiving Therapy For Systemic Fungal Infections
Systemic Fungal Infections
Primary: Diagnosis of Systemic Fungal Infection (SFI) — 20; 6; 18; 3 Participants
Phase 4 N=132 Scoring Clinical Index For Onychomycosis in Toenail Onychomycosis Treating With Itraconazole Capsules
Onychomycosis, Toe
Primary: Percentage of Participants Showing 10 Percent or Higher Response in Scoring Clinical Index for Onychomycosis (SCIO) Score at Week 5 — 25.6 percentage of participants
Phase 2 N=20 Treatment of Corneal Neovascularization With Topical Pazopanib
Corneal Neovascularization
Primary: Heart Rate — 68.7 Beats per Minutes
Phase 4 N=167 Comparison of Corticosteroid Dosing Regimens After Endothelial Keratoplasty
Fuchs' Dystrophy · Corneal Edema
Primary: Intraocular Pressure — 11; 27 eyes
Phase 4 N=13 Confocal Analysis of Corneal Structures of Symptomatic Allergic Conjunctivitis Patients
Allergic Conjunctivitis
Primary: Patient-Assessed Ocular Itching — 2.2; 2.2; 0.5; 0.5 units on a scale
N/A N=40 Sutureless Cryopreserved Amniotic Membrane Graft (ProKera) and Wound Healing After Photorefractive Keratectomy
Corneal Wound Healing
Primary: Number of Days to Complete Re-epithelialization — 4.6; 4.1 days to complete re-epithelialization
N/A N=120 Microbiological Evaluation of the Ocular Flora Before Cataract Surgery
Disorders of the Eye Following Cataract Surgery
Primary: Positive Culture in Subjects Scheduled for Cataract Surgery — 87 subjects
Phase 2 N=203 Evaluate F901318 (Olorofim) Treatment of Invasive Fungal Infections in Participants Lacking Treatment Options
Invasive Fungal Infections
Primary: Data Review Committee (DRC) Adjudicated Overall Response at Day 42 — 28.7 Response rate percentage